Peptides for Muscle Growth: Separating Mechanism From Evidence

Three distinct approaches get grouped under this heading, and they act at different points on the same axis. Growth hormone secretagogues work upstream. IGF-1 analogues work downstream. Myostatin-pathway compounds work on a separate brake entirely.

What they have in common is that the human evidence for muscle growth in healthy people is thin to absent, whatever the mechanism suggests.

The axis, and where each approach acts

The distinction in the last column matters more than the mechanism. Secretagogues ask the pituitary to release more of what it makes, so the ceiling is the body’s. IGF-1 LR3 is engineered to evade the binding proteins that regulate it, which removes that ceiling deliberately.

Growth hormone secretagogues

The most commonly discussed group, and the one with the most benign profile. Ipamorelin is favoured for its selectivity; hexarelin produces a larger response but desensitises quickly and raises cortisol and prolactin.

They are frequently paired with a GHRH analogue on the grounds that the two act on different receptors — see the CJC-1295 and ipamorelin guide.

The myostatin brake

Myostatin limits muscle growth. Follistatin binds and inhibits it, which is why follistatin analogues attract attention — the idea is to release a brake rather than press an accelerator.

The dramatic images associated with this pathway come from animals and rare humans with natural myostatin-pathway mutations, where the deficiency was present throughout development. That is not the same as inhibiting it in an adult. See the follistatin guide.

What the evidence actually supports

• In deficiency states, GH and IGF-1 therapies have established clinical roles. That is where the approvals are.

• In healthy adults, controlled evidence that these compounds add meaningful muscle beyond training and nutrition is largely absent.

• For follistatin/myostatin, the best-evidenced intervention in the published record is unglamorous: resistance exercise combined with adequate amino acid intake shifts the follistatin/myostatin ratio in randomised work.

Frequently asked questions

Do GH secretagogues build muscle?

They raise growth hormone, which is well documented. That raised GH produces meaningful muscle growth in healthy trained adults is not established by controlled evidence.

Is IGF-1 LR3 more effective than secretagogues?

It acts more directly and bypasses regulation, which is exactly why it carries considerations the secretagogues do not — including hypoglycaemia risk and unregulated proliferative signalling.

Are these detectable in drug testing?

Yes. This category is a specific focus of anti-doping testing, and prohibition applies regardless of whether a compound is otherwise lawful.